Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

481 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Elliott M, Mangaonkar A, Matin A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Yates S, Sneider A, Dworkin E, Patel AA, Bazinet A, Senapati J, Bataller A, DiNardo C, Kadia T, Tefferi A. Gangat N, et al. Among authors: kadia t. Am J Hematol. 2024 Dec 13. doi: 10.1002/ajh.27564. Online ahead of print. Am J Hematol. 2024. PMID: 39671248
Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy.
Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Sasaki K, et al. Among authors: kadia t. Am J Hematol. 2022 Jan 1;97(1):68-78. doi: 10.1002/ajh.26395. Epub 2021 Nov 9. Am J Hematol. 2022. PMID: 34716921 Free article.
A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.
Tefferi A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Ketterling RP, DiNardo CD, Kadia TM, Ravandi F, Sasaki K, Begna KH. Tefferi A, et al. Am J Hematol. 2022 Sep;97(9):1127-1134. doi: 10.1002/ajh.26630. Epub 2022 Jun 30. Am J Hematol. 2022. PMID: 35702875 Free article.
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G. Al-Kali A, et al. Among authors: kadia t. Am J Hematol. 2013 May;88(5):365-9. doi: 10.1002/ajh.23410. Epub 2013 Mar 20. Am J Hematol. 2013. PMID: 23512829 Free PMC article.
Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome.
Badar T, Shetty A, Bueso-Ramos C, Cortes J, Konopleva M, Borthakur G, Pierce S, Huang X, Chen HC, Kadia T, Daver N, Dinardo C, O'Brien S, Garcia-Manero G, Kantarjian H, Ravandi F. Badar T, et al. Among authors: kadia t. Am J Hematol. 2015 Sep;90(9):769-73. doi: 10.1002/ajh.24074. Epub 2015 Jul 27. Am J Hematol. 2015. PMID: 26017166 Free PMC article. Clinical Trial.
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. DiNardo CD, et al. Among authors: kadia t. Am J Hematol. 2018 Mar;93(3):401-407. doi: 10.1002/ajh.25000. Epub 2017 Dec 23. Am J Hematol. 2018. PMID: 29218851 Free article.
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Maiti A, et al. Am J Hematol. 2021 Mar 1;96(3):282-291. doi: 10.1002/ajh.26061. Epub 2020 Dec 24. Am J Hematol. 2021. PMID: 33264443 Free PMC article.
Development of TP53 mutations over the course of therapy for acute myeloid leukemia.
Alwash Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, Daver N, Ravandi F, Kadia TM, Konopleva M, Dinardo CD, Issa GC, Loghavi S, Takahashi K, Jabbour E, Guerra V, Kornblau S, Kantarjian H, Short NJ. Alwash Y, et al. Am J Hematol. 2021 Nov 1;96(11):1420-1428. doi: 10.1002/ajh.26314. Epub 2021 Aug 19. Am J Hematol. 2021. PMID: 34351647 Free PMC article.
481 results